Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Case Report

Published on 10 Jan 2023

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

in Cancer Molecular Targets and Therapeutics

Wen-Chi Wu
Ming-Huang Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.1031396

2,064 views
1 citation

Brief Research Report

Published on 10 Jan 2023

Mild oxidative stress protects against chemotherapy-induced hair loss

in Cancer Molecular Targets and Therapeutics

Yusheng Zhang
Joaquin J. Jimenez

Frontiers in Oncology

doi 10.3389/fonc.2022.1078916

3,243 views
2 citations

Review

Published on 10 Jan 2023

Potassium channels: Novel targets for tumor diagnosis and chemoresistance

in Cancer Molecular Targets and Therapeutics

Meizeng Li
Peijie Tian
Qing Zhao
Xialin Ma
Yunxiang Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1074469

6,253 views
27 citations

Review

Published on 09 Jan 2023

CircCCDC66: Emerging roles and potential clinical values in malignant tumors

in Cancer Molecular Targets and Therapeutics

Xiaoxiao Wang
Chao Zhang
Huangqin Song
Junlong Yuan
Lei Zhang
Jiefeng He

Frontiers in Oncology

doi 10.3389/fonc.2022.1061007

3,757 views
8 citations

Correction

Published on 06 Jan 2023

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

in Cancer Molecular Targets and Therapeutics

Sunisa Prasopporn
Orawan Suppramote
Ben Ponvilawan
Chanette Jamyuang
Jantappapa Chanthercrob
Amphun Chaiboonchoe
Pimkanya More-Krong
Kamonchanok Kongsri
Monthira Suntiparpluacha
Rawisak Chanwat

Frontiers in Oncology

doi 10.3389/fonc.2022.1124912

1,423 views
1 citation

Review

Published on 06 Jan 2023

Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening

in Cancer Molecular Targets and Therapeutics

Cuiying Xie
Ancheng Gu
Muhammad Khan
Xiangcao Yao
Leping Chen
Jiali He
Fumiao Yuan
Ping Wang
Yufan Yang
Yerong Wei

Frontiers in Oncology

doi 10.3389/fonc.2022.1105454

4,544 views
10 citations

Systematic Review

Published on 05 Jan 2023

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

in Cancer Molecular Targets and Therapeutics

Peizhuo Yao
Yinbin Zhang
Shuqun Zhang
Xinyu Wei
Yanbin Liu
Chong Du
Mingyou Hu
Cong Feng
Jia Li
Fang Zhao

Frontiers in Oncology

doi 10.3389/fonc.2022.1039882

6,941 views
15 citations

Original Research

Published on 04 Jan 2023

Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models

in Cancer Molecular Targets and Therapeutics

Aurimas Stulpinas
Matas Sereika
Aida Vitkeviciene
Ausra Imbrasaite
Natalija Krestnikova
Audrone V. Kalvelyte

Frontiers in Oncology

doi 10.3389/fonc.2022.1045521

4,143 views
10 citations

Original Research

Published on 04 Jan 2023

A pan-cancer landscape of IGF2BPs and their association with prognosis, stemness and tumor immune microenvironment

in Cancer Molecular Targets and Therapeutics

Wei Shao
Hui Zhao
Shoudu Zhang
Qian Ding
Yugang Guo
Kaiqi Hou
Yunchao Kan
Fan Deng
Qian Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.1049183

4,733 views
16 citations

Original Research

Published on 23 Dec 2022

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

in Cancer Molecular Targets and Therapeutics

Yezhe Cheng
Xiaoxi Yuan
Qiang Tian
Xiuying Huang
Yang Chen
Yuzhi Pu
Hu Long
Mingyu Xu
Yafei Ji
Jia Xie

Frontiers in Oncology

doi 10.3389/fonc.2022.951589

35,849 views
42 citations

Brief Research Report

Published on 23 Dec 2022

Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study

in Cancer Molecular Targets and Therapeutics

Darshana Patil
Dadasaheb Akolkar
Rajnish Nagarkar
Navin Srivastava
Vineet Datta
Sanket Patil
Sachin Apurwa
Ajay Srinivasan
Rajan Datar

Frontiers in Oncology

doi 10.3389/fonc.2022.972322

2,474 views
4 citations

Review

Published on 22 Dec 2022

LINC00324 in cancer: Regulatory and therapeutic implications

in Cancer Molecular Targets and Therapeutics

Qing Xia
Jinze Shen
Qurui Wang
Yufei Ke
Qibin Yan
Hanbing Li
Dayong Zhang
Shiwei Duan

Frontiers in Oncology

doi 10.3389/fonc.2022.1039366

2,497 views
9 citations

Review

Published on 22 Dec 2022

The role and mechanism of claudins in cancer

in Cancer Molecular Targets and Therapeutics

De-Wen Wang
Wei-Han Zhang
Galiullin Danil
Kun Yang
Jian-Kun Hu

Frontiers in Oncology

doi 10.3389/fonc.2022.1051497

10,207 views
43 citations

Case Report

Published on 22 Dec 2022

Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma

in Cancer Molecular Targets and Therapeutics

Xiangming Fang
Haibo Mou
Xinxin Ying
Xuehua Hou
Luo Wang
Ying Wu
Naimeng Yan
Lijie Guo
Qin Liao

Frontiers in Oncology

doi 10.3389/fonc.2022.1024677

2,077 views
3 citations

Original Research

Published on 19 Dec 2022

Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma

in Cancer Molecular Targets and Therapeutics

Jie Wei
Jianfeng Wu
Zhiyong Yin
Xia Li
Yixiong Liu
Yingmei Wang
Zhe Wang
Chao Xu
Linni Fan

Frontiers in Oncology

doi 10.3389/fonc.2022.1048482

1,897 views
4 citations

Review

Published on 16 Dec 2022

The role of IL-6/JAK2/STAT3 signaling pathway in cancers

in Cancer Molecular Targets and Therapeutics

Bei Huang
Xiaoling Lang
Xihong Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1023177

28,723 views
228 citations